Skip to main navigation
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
 
 
  • Home
  • Our Company
    • About Iovance Biotherapeutics
    • Management
    • Board of Directors
    • Research Partners & Collaborators
  • Our Science
    • About TIL
    • Our T-cell Therapy Platforms
    • Scientific Publications & Presentations
    • Next Generation Research
  • Our Technology
    • Iovance Cell
      Therapy Center
    • Manufacturing
    • Intellectual Property
  • Our Pipeline
    • Clinical Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Careers
    • Current Opportunities
    • Our Culture
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn

Investor Overview

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Ownership Summary
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Earnings Estimates
  • Fundamentals
    • Snapshot
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
Investor Toolkit
  • Print Page
  • RSS
  • Email Alerts

Latest News

  • Aug 04, 2022 Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
  • Jul 27, 2022 Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
  • Jul 22, 2022 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
View All News

Latest Events

  • Aug 4, 2022 at 4:30 PM EDT
    Iovance Biotherapeutics Second Quarter 2022 Earnings Conference Call
  • Jun 15, 2022 at 6:20 PM EDT
    Goldman Sachs Global Healthcare Conference
  • Jun 15, 2022 at 2:30 PM EDT
    JMP Securities Life Sciences Conference
View All Events

Latest Financial Results

Show all
Show All

2022 Quarterly Results

Q2 Earnings
  • Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
  • Iovance Biotherapeutics Second Quarter 2022 Earnings Conference Call
  • Form 10-Q
View All Financial Results
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
© 2022 IOVANCE Biotherapeutics, Inc. All Rights Reserved. IOVANCE logo is a trademark owned
by IOVANCE Biotherapeutics, Inc.
  • Privacy Notice
  • Terms of Use
COOKIE NOTIFICATION

This website uses cookies to improve the site and user experience. By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our cookie policy.

Accept